BCOP case studies
BCOP · Put your knowledge to work in context.
The Board-Certified Oncology Pharmacist (BCOP®) credential is conferred by the Board of Pharmacy Specialties (BPS) on pharmacists who pass the Oncology Pharmacy specialty certification examination. BPS describes the target population as pharmacists who design, implement, monitor, and modify pharmacotherapeutic treatments; manage adverse events or clinical situations associated with cancer, cancer therapies, and non-malignant hematology; and facilitate and/or evaluate clinical trials, research, and investigational drugs. The BCOP case studies are 5 cases and about 4,145 words.
1Renal Function Threshold in First-Line NSCLC: Is Pemetrexed an Option?
A 68-year-old woman with newly diagnosed metastatic non-squamous NSCLC (PD-L1 TPS 30%, no EGFR, ALK, ROS1, or KRAS G12C driver) is planned for carboplatin AUC 6 + pemetrexed 500 mg/m2 + pembrolizumab. Height 160 cm, weight 58 kg, serum creatinine 1.5 mg/dL.
743 words, about 4 min2Grade 3 Immune-Mediated Colitis on Nivolumab plus Ipilimumab
A 58-year-old woman with unresectable BRAF wild-type stage IV melanoma is receiving nivolumab 1 mg/kg plus ipilimumab 3 mg/kg every 3 weeks; today is day 12 after her second dose. She reports 8 watery stools per day above baseline for 3 days, with urgency and cramping.
756 words, about 4 min3Newly Diagnosed ITP in a Patient With Diabetes and Severe Osteoporosis
A 74-year-old woman is diagnosed with primary immune thrombocytopenia after an isolated platelet count of 21 x 10^9/L on two occasions, with petechiae on her shins and gum bleeding when brushing her teeth. She has no lymphadenopathy, no hepatosplenomegaly, and otherwise normal blood counts.
803 words, about 4 min4Opioid Neurotoxicity and Rotation in Advanced Prostate Cancer With Renal Failure
A 66-year-old man with metastatic castration-resistant prostate cancer and diffuse bone metastases has pain 6/10 despite morphine sulfate extended-release 60 mg PO every 12 hours plus morphine immediate-release 15 mg PO every 2 hours as needed, of which he has used four doses daily for the past two weeks. Over five days he has developed increasing sedation, intermittent myoclonus, and new confusion; his wife says he is 'hard to wake' between doses.
848 words, about 4 min5Phase I Eligibility, DLT Adjudication, and Consent on a First-in-Human ATR Inhibitor Trial
A 61-year-old woman with platinum-resistant high-grade serous ovarian cancer progressing after three prior lines (including a PARP inhibitor and liposomal doxorubicin) is being screened for a first-in-human phase I trial of an oral ATR inhibitor given continuously in 28-day cycles, with a 28-day DLT window and a 3+3 design. Screening labs: ANC 1.3 x 10^9/L, platelets 92 x 10^9/L, hemoglobin 9.6 g/dL, AST 2.7x ULN, ALT 1.8x ULN, total bilirubin 1.0 mg/dL, albumin 3.1 g/dL, Cockcroft-Gault CrCl 52 mL/min.
995 words, about 5 min